{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:16:45Z","timestamp":1762521405901},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.reuma.2010.11.002","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T09:27:55Z","timestamp":1292664475000},"page":"30-44","source":"Crossref","is-referenced-by-count":8,"title":["Consenso de uso de rituximab en artritis reumatoide. Un documento con recomendaciones basadas en la evidencia"],"prefix":"10.1016","volume":"7","author":[{"given":"Emilio","family":"Mart\u00edn Mola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Garc\u00eda-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"\u00c1lvaro-Gracia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan G\u00f3mez","family":"Reino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Marenco de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Mart\u00ednez-Taboada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Andr\u00e9s Rom\u00e1n","family":"Ivorra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2010.11.002_bib0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.reuma.2010.11.002_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans."},{"key":"10.1016\/j.reuma.2010.11.002_bib0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2010.11.002_bib0020","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2010.11.002_bib0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.reuma.2009.10.006","article-title":"Actualizaci\u00f3n del documento de consenso de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el uso de terapias biol\u00f3gicas en la artritis reumatoide","volume":"6","author":"Tornero","year":"2010","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2010.11.002_bib0035","article-title":"The RAND\/UCLA Appropriateness Method User's Manual","author":"Fitch","year":"2001","journal-title":"Santa Monica: RAND"},{"key":"10.1016\/j.reuma.2010.11.002_bib0040","first-page":"555","article-title":"Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee","volume":"20","author":"Tugwell","year":"1993","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2010.11.002_bib0045","unstructured":"Oxford center for evidence based medicine levels of evidence, 2009. Disponible en: htpp:\/\/www.cmbd.net."},{"key":"10.1016\/j.reuma.2010.11.002_bib0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0055","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0060","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0065","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0070","first-page":"75","volume":"68","author":"Tak","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 1","key":"10.1016\/j.reuma.2010.11.002_bib0075","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","article-title":"Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review","volume":"11","author":"Rubbert-Roth","year":"2009","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2010.11.002_bib0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0085","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2010.11.002_bib0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/03009740902946355","article-title":"Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients","volume":"38","author":"Valleala","year":"2009","journal-title":"Scand J Rheumatol."},{"key":"10.1016\/j.reuma.2010.11.002_bib0095","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0100","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/ard.2009.119222","article-title":"Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate","volume":"69","author":"Cohen","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0105","first-page":"S247","article-title":"Efficacy of rituximab in active RA patients with an inadecuate response to one or more TNF inhibitors [abstract]","volume":"54 Suppl","author":"Kremer","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0110","first-page":"379","article-title":"Switching to RTX and an alternative TNF inhibitor in patients with rheumatoid arthritis (RA) that have failed previous TNF inhibitor(s) are both effective treatment options with good maintenance rates [abstract]","volume":"69","author":"Buch","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0115","first-page":"442","article-title":"Rituximab compared with further tumour necrosis factor (TNF) antagonist therapy in rheumatoid arthritis (RA) patients who had previously failed TNF antagonist therapy: results of a prospective, observational study [abstract]","volume":"68","author":"G\u00f3mez-Reino","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0120","first-page":"833","article-title":"Baseline autoantibody status (RF, anti-CCP) and clinical response following the first treatment course with rituximab [abstract]","volume":"54 Suppl","author":"Tak","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"Suppl II","key":"10.1016\/j.reuma.2010.11.002_bib0125","first-page":"338","article-title":"Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF,anti-CCP) (abstract)","volume":"66","author":"Tak","year":"2007","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0130","first-page":"442","article-title":"Autoantibody-positive rheumatoid arthritis (RA) patients (PTS) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients [abstract]","volume":"68","author":"Isaacs","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2010.11.002_bib0135","first-page":"1687","article-title":"Effectiveness of rituximab (RTX), methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease characteristics associated with poor outcomes [abstract]","volume":"60","author":"Mariette","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0140","first-page":"579","article-title":"Effect of concomitant DMARD on B cell depletion with rituximab in rheumatoid arthritis [abstract]","volume":"68","author":"Dass","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0145","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/ard.2007.087023","article-title":"Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate","volume":"67","author":"Owczarczyk","year":"2008","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0150","first-page":"741","article-title":"How effective is rituximab in rheumatoid arthritis? Lessons learned from clinical practice [abstract]","volume":"68","author":"Schmidt","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0155","first-page":"438","article-title":"Rheumatoid arthritis treated with rituximab in the real life: efficacy depend on rheumatoid factor positivity but not on methotrexate association or previous treatment with anti-TNF alpha [abstract]","volume":"68","author":"Prudhomme","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0160","first-page":"76","article-title":"Effectiveness and safety of rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) or leflunomide (LEF) in the german RTX treatment of active rheumatoid arthritis (RA) in daily practice trial [abstract]","volume":"68","author":"Wendler","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0165","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00296-009-1302-z","article-title":"Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis","volume":"30","author":"Henes","year":"2010","journal-title":"Rheumatol Int."},{"issue":"Suppl II","key":"10.1016\/j.reuma.2010.11.002_bib0170","first-page":"90","article-title":"Combination rituximab and leflunomide produces lasting responses in rheumatoid arthritis","volume":"67","author":"Vital","year":"2008","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0175","first-page":"581","volume":"68","author":"Rigby","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0180","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3899\/jrheum.090442","article-title":"Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial","volume":"37","author":"Mease","year":"2010","journal-title":"J Rheumatol."},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2010.11.002_bib0185","first-page":"1683","article-title":"Multiple courses of rituximab (RTX) produce sustained efficacy in patients (pts) with rheumatoid arthritis (RA) with an inadequate response (IR) to one or more TNF inhibitors [abstract]","volume":"60","author":"Keystone","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0190","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0195","unstructured":"Ficha t\u00e9cnica de Mabthera. Hoffman La Roche; 2009."},{"key":"10.1016\/j.reuma.2010.11.002_bib0200","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ard.2008.100438","article-title":"Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2010.11.002_bib0205","first-page":"680","article-title":"Comparision of clinical outcome in rheumatoid arthritis patients treated with a fixed or on-demand regime of rituximab: two year follow up [abstract]","volume":"60","author":"Tekstra","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2010.11.002_bib0210","first-page":"2013","article-title":"Retreatment with rituximab (RTX) based on a treatment to target (TT) approach provides better disease control than treatment as needed (PRN) in patients (pts) with rheumatoid arthritis (RA)","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0215","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/art.24035","article-title":"Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders","volume":"58","author":"Thurlings","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0220","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","article-title":"Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment","volume":"62","author":"Vital","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2010.11.002_bib0225","first-page":"379","article-title":"Switching to rituximab and an alternative inhibitor in patients with rheumatoid arthritis (RA) that have failed previous TNF inhibitor(s) are both effective treatment options with good maintenance rates","volume":"69","author":"Buch","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0230","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","article-title":"Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment","volume":"56","author":"Teng","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0235","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0240","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0245","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0250","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0255","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2010.11.002_bib0260","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"Van Vollenhoven","year":"2010","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2010.11.002_bib0265","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab (AIR) registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"Van","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0275","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0280","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0285","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1136\/ard.2008.101675","article-title":"Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients","volume":"68","author":"Genovese","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2010.11.002_bib0290","first-page":"1957","article-title":"Safety of rituximab in combination with a TNF inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial (TAME) [abstract]","volume":"60","author":"Greenwald","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0295","first-page":"371","article-title":"RA patients treated with rituximab\u2014routine care data of the german biologics register RABBIT [abstract]","volume":"58 Suppl","author":"Strangfeld","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0300","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA."},{"key":"10.1016\/j.reuma.2010.11.002_bib0305","first-page":"1010","article-title":"No increased risk of solid tumours in patients treated with biologics [abstract]","volume":"58 Suppl","author":"Strangfeld","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0310","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0315","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0320","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0325","first-page":"1344","article-title":"Are cancers occurring in RA patients treated with TNF-antagonists particularly aggressive? [abstract]","volume":"56 Suppl","author":"Raaschou","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0330","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2010.11.002_bib0335","first-page":"31","article-title":"Rituximab therapy in rheumatoid arthritis in daily practice","volume":"35","author":"Assous","year":"2008","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2010.11.002_bib0340","article-title":"The use of biologic therapy in patients with RA and existing cancer","volume":"54 Suppl","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0345","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000163069","article-title":"Rituximab-induced hypersensitivity pneumonitis","volume":"78","author":"Tonelli","year":"2009","journal-title":"Respiration."},{"key":"10.1016\/j.reuma.2010.11.002_bib0350","first-page":"1083","volume":"50","author":"Ram","year":"2009","journal-title":"The late adverse events of rituximab therapy\u2014rare but there! Leuk Lymphoma."},{"key":"10.1016\/j.reuma.2010.11.002_bib0355","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1445-5994.2006.01055.x","article-title":"Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports","volume":"36","author":"Lim","year":"2006","journal-title":"Intern Med J."},{"key":"10.1016\/j.reuma.2010.11.002_bib0360","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","article-title":"Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab","volume":"47","author":"McGonagle","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2010.11.002_bib0365","article-title":"Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab","author":"Yoo","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reuma.2010.11.002_bib0370","first-page":"3788","article-title":"[TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports]","volume":"102","author":"Tengstrand","year":"2005","journal-title":"Lakartidningen."},{"key":"10.1016\/j.reuma.2010.11.002_bib0375","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/art.21716","article-title":"Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab","volume":"55","author":"Schoe","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2010.11.002_bib0380","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology."},{"key":"10.1016\/j.reuma.2010.11.002_bib0385","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.reuma.2010.11.002_bib0390","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann Hematol."},{"key":"10.1016\/j.reuma.2010.11.002_bib0395","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.reuma.2010.11.002_bib0400","article-title":"Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis","author":"Pyrpasopoulou","year":"2009","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.reuma.2010.11.002_bib0405","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez Cruz B, Garc\u00eda Arias M, Ariza Ariza R, Mart\u00edn Mola E. Rituximab en artritis reumatoide. Una revisi\u00f3n sistem\u00e1tica. Reumatol Clin. 2010.[en prensa].","DOI":"10.1016\/j.reuma.2011.03.004"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X10002238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X10002238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T20:58:45Z","timestamp":1592168325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X10002238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1699258X10002238"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2010.11.002","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}